Powerus, a US defense company with ties to President Donald Trump’s sons, drew scrutiny after signing a memorandum of understanding this month with the Pakistani Army and offering Islamabad access to Ukrainian drone technology, sparking debate over the deal’s potential impact on India and wider regional security. Powerus was founded in October 2025 by veterans […]
Devastated relatives who arrived from abroad visited the site of the collapsed building where four tourists and an elderly couple lost their lives on Friday morning, September 25, 2026. With tears in their eyes and broken voice they told media reporters that they came for the identification of the victims adding that the recognition was […]
What follows is twelve documented findings compressed into one sitting. It is written for the reader who has been prescribed one of these drugs, or is caring for someone who has, and who wants to know what the fifteen-minute consultation did not include. Every claim is drawn from the profession’s own literature, its own regulatory filings, its own package inserts, or the admissions of its own senior figures. Where an item is developed at greater length elsewhere in this series, that is noted. The purpose here is not depth on any single item. It is the cumulative weight of the twelve landing together.
Opening
Three percent of the 4,041 patients enrolled in the STAR*D trial remitted, stayed well, and remained in the study through the one-year follow-up.¹
The trial was announced with a cumulative remission figure of 67 percent.² When Ed Pigott and colleagues spent more than five years reanalyzing the data with fidelity to the original protocol, they found the 3 percent figure. When journalists put the 3 percent number to Maurizio Fava, one of the lead investigators, he acknowledged it was accurate. The investigators knew.³
The paper has not been retracted. It is still cited in psychiatric textbooks. The American Journal of Psychiatry ignored a petition signed by more than 1,800 people asking for retraction. The New York Times, repeatedly notified of the fraud, published the 70 percent figure again in a 2024 article praising the drugs.⁴
STAR*D was the largest depression trial ever conducted. It was funded by the National Institute of Mental Health. It was designed by the profession’s most senior researchers. What it proved, when honestly analyzed, was that the drugs did not work.
That fact has been available for over a decade. It has not reached the patients being handed the prescriptions.
What This Essay Draws On
Six of the twelve items below have been developed at greater length in earlier essays in this series: chemical imbalance theory, benzodiazepine dependence, ADHD stimulants, antipsychotic brain damage, SSRI withdrawal, and long-term antidepressant outcomes. Readers who want depth on any of those threads should follow them. The purpose of this essay is different. Twelve items, four sections, one sitting.
The evidence throughout is drawn primarily from Peter Gøtzsche, Robert Whitaker, Peter Breggin, Gary Greenberg, David Healy, and Joanna Moncrieff. What the twelve items share is that none of them are contested at the level of documentation. They are contested only at the level of what the profession chooses to tell patients.
What They Told You Was True
The prescription is written on the basis of a mechanism, a diagnosis, and a trial. Each has failed on its own terms.
1. The chemical imbalance was never demonstrated
The theory that depression results from a deficiency of serotonin was never established in the scientific literature. Joanna Moncrieff and colleagues published a comprehensive umbrella review of the serotonin theory in 2022 and found no consistent evidence for its central claims.⁵ The theory was abandoned by serious researchers decades earlier. It continued to appear in direct-to-consumer advertising and patient education materials because it served a function. It explained why the pill was necessary and why the patient would need to keep taking it.
Steven Hyman, director of NIMH from 1996 to 2001, later observed that “the gold standard was the DSM criteria. It struck me as a fool’s errand to try to develop a biomarker for a fictive category.”⁶ The chemical imbalance was the mechanism proposed for a disease no one could measure, in a category no one could validate.
After four decades and hundreds of millions of dollars in federal research, not one disorder in the Diagnostic and Statistical Manual of Mental Disorders has a confirmed biological test. Not depression. Not schizophrenia. Not bipolar disorder. Not ADHD. Not anxiety. Not any of the more than three hundred conditions the manual lists.
Robins and Guze proposed a five-step validation process in 1970: clinical description, laboratory studies, exclusion criteria, follow-up studies, family studies.⁷ The five steps were meant to establish, over time, which alleged disorders were real diseases and which were figments. Four decades later, Darrel Regier, who chaired the DSM-5 task force, told Psychiatric News that “validity tests have not lived up to the expectations of Robins and Guze.”⁸ Kenneth Kendler, the field’s leading nosologist, wrote that the diagnostic categories in use had been “heavily influenced by expert opinion” and were “fuzzy constructs that shift when viewed in different ways.”⁹
Thomas Insel, director of NIMH from 2002 to 2015, put it most directly in a 2005 address to the American Psychiatric Association: “The DSM-IV has 100 percent reliability and zero percent validity.”¹⁰ Reliability means clinicians using the same manual will arrive at the same diagnosis. Validity means the diagnosis corresponds to a real thing. Insel was telling the assembled profession that its manual sorted patients consistently into categories that did not exist.
The APA response was to convene committees to plan the DSM-5. The committees did not find biological markers. They could not have. The categories were not built to have biological markers. They were built from clinical description alone. The manual reifies its own criteria.
The consequence for the patient is direct. When the doctor says “you have major depressive disorder,” the patient hears a diagnosis in the sense that a diabetes diagnosis is a diagnosis: a measurable biological state with a known mechanism. What the patient has actually received is a checklist tally. Five of nine symptoms present for two weeks. That is the whole test. There is no blood work, no scan, no biomarker. The diagnostic bible of American psychiatry sits on the shelf as an artifact of expert agreement, not a description of nature.
The opening figures bear structural repetition: 3 percent versus 67 percent, admitted by the lead investigator, still not retracted, still cited. Ed Pigott’s reanalysis was published in BMJ Open in 2023.¹¹ The investigators, when confronted, doubled down on the fraud in the American Journal of Psychiatry rather than correct it.¹² The owner of the journal, the American Psychiatric Association, did nothing.
Peter Gøtzsche has documented the specific manipulations. The “remission” threshold was set so low that a patient scoring 7 on the Hamilton depression scale, including endorsement of “feels like life is not worth living,” was counted as symptom-free.¹³ Patients who exited the study were assumed to have remitted at the same rate as those who stayed, a statistical fiction that inflated the numbers by an order of magnitude. Eleven prespecified outcomes were never reported. Suicidal ideation was reported at 0.7 percent in one paper and ten times that in others by the same authors.
The trial that was supposed to establish the effectiveness of antidepressants in real-world practice established the opposite. The profession’s response was to continue citing the announced figure.
The prescription arrives with the phrase “you may notice some side effects.” The phrase does the work of concealment. Three effects, in particular, are not warned about with the seriousness they warrant.
4. Akathisia carries documented suicide risk
Akathisia is a state of extreme inner restlessness produced by antidepressants, antipsychotics, and antiemetics. The Greek term means inability to sit still. The patient may pace, fidget, wring hands, or endlessly walk. The condition may also present without visible motor symptoms, as unbearable internal agitation the observer cannot see.¹⁴
In 1990, Martin Teicher and colleagues at Harvard published five cases of patients who developed intense suicidal preoccupations on fluoxetine, all associated with akathisia, all resolving when the drug was stopped and returning when it was restarted.¹⁵ Rothschild and Locke published the rechallenge study in 1991: three patients who had made serious suicide attempts on fluoxetine, all rechallenged under controlled conditions, all developing akathisia and becoming suicidal again. One patient said in retrospect: “I tried to kill myself because of these anxiety symptoms. It was not so much the depression.”¹⁶
A study of psychiatric inpatients found that 79 percent of those who had attempted suicide were experiencing akathisia at the time.¹⁷ Another found that half of all fights on a psychiatric ward were akathisia-related. Haloperidol at moderate to high doses made half the patients markedly more aggressive, sometimes to the point of wanting to kill their psychiatrists.
The FDA’s 2004 black-box warning on antidepressants describes what Breggin has called the stimulant syndrome: anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania.¹⁸ The label warns that these can occur in nonpsychiatric patients, meaning the drug produces the syndrome by itself, not by unmasking a preexisting condition.
Gøtzsche’s team examined manufacturer trial data and found akathisia miscoded as “hyperkinesia” in Zoloft trials. In paroxetine trials they found not a single case of akathisia recorded, which is statistically impossible given the drug class.¹⁹ The miscoding was systematic.
The FDA-approved label for Zyprexa describes akathisia as “extreme inner anxiety and restlessness.” At least one psychiatric textbook labeled it “agitated depression,” folding the drug’s most dangerous effect back into the diagnosis it was prescribed to treat. The patient who reports the akathisia is told the underlying illness has worsened. The dose is increased.
5. Benzodiazepine dependence begins at prescribed doses
The FDA-approved label for Xanax states that withdrawal symptoms, including seizures, have been reported after only brief therapy at doses within the recommended range for treating anxiety.²⁰ In the eight-week trials used for FDA approval, patients were worse off at eight weeks than before starting the drug. Between 7 and 29 percent of patients could not withdraw after only six to eight weeks of exposure.²¹
If you are currently taking a benzodiazepine, do not stop it abruptly. Abrupt cessation can produce seizures. Item 12 addresses what safe withdrawal actually requires.
Heather Ashton, the British psychiatrist who ran a benzodiazepine withdrawal clinic at the University of Newcastle for decades, documented that long-term users often required a year or more to taper.²² Some experience withdrawal symptoms lasting years after cessation. Cognitive impairment, depression, and anxiety worse than the original condition are common outcomes of long-term use.²³ Gøtzsche, who has decades of clinical pharmacology experience, has noted that patients report benzodiazepine withdrawal as often worse than heroin. Heroin abstinence symptoms resolve within days. Benzo withdrawal can persist for years.
6. ADHD stimulants produce the symptoms they treat on withdrawal
The DSM has a category for stimulant withdrawal, which lists depression, anxiety, irritability, sleep problems, fatigue, and agitation as the withdrawal syndrome after “several days or longer” of use. Rebound hyperactivity, talkativeness, and inattention are documented after a single dose in a placebo-controlled NIMH study of normal children ages 6 to 12.²⁴ Ten of fourteen children in that study showed marked behavioral rebound; three developed euphoria.
If a child is currently taking a stimulant, do not stop it abruptly. Rebound and withdrawal effects are commonly mistaken for a worsening of the original condition. Item 12 addresses safe withdrawal.
The teacher observes the child on Monday morning after a weekend off the drug, notices the child is more scattered and irritable than usual, and concludes the child needs the medication. The child is in withdrawal. The dose is increased. Peter Breggin’s observation from the early 1990s stands unchanged three decades later: if the child continues on Ritalin because they continue to have problems focusing, the disorder may be the drug’s effect.²⁵ Drug-induced inattention becomes the reason to continue and increase the drug.
The Multimodal Treatment Study of ADHD, the largest NIMH-funded stimulant trial, tracked children through eight years of follow-up. By three years, the medicated children showed no advantage over the non-medicated on any measure. They were, however, 2 cm shorter and 2.7 kg lighter than their unmedicated peers, a growth suppression the FDA eventually required on the label.²⁶
The drugs act on the brain and the brain responds. What the brain does under sustained chemical assault is documented in the profession’s own imaging studies.
7. Antipsychotics shrink brain tissue on MRI
Nancy Andreasen, editor-in-chief of the American Journal of Psychiatry from 1993 to 2005, began a longitudinal MRI study of over 500 first-episode schizophrenia patients in 1989. In 2003, she reported that frontal lobe white matter volume decreased progressively over the years of treatment.²⁷ In 2011, her team published in Archives of General Psychiatry the finding that antipsychotic exposure was directly associated with volume loss.²⁸ In a 2008 interview with the New York Times, Andreasen stated it plainly: “The more drugs you’ve been given, the more brain tissue you lose.”²⁹
Fusar-Poli and colleagues confirmed the pattern in a 2013 meta-analysis of longitudinal MRI studies.³⁰ The 2009 Navari and Dazzan review reported that both older and newer antipsychotics produce gross changes in brain volume in selected regions.³¹ In monkey studies, haloperidol and olanzapine produced substantial reductions in both grey and white matter, and reduced glial cell numbers.³²
Andreasen’s original interpretation was that the shrinkage reflected the disease. The follow-up data forced her to concede the drug was the cause.
Tardive dyskinesia is a drug-induced movement disorder produced by antipsychotics. It can affect any voluntary muscle: face, tongue, neck, torso, extremities, diaphragm, vocal cords. The condition presents as involuntary jerky movements, slower writhing movements, painful spasms, or restlessness the patient cannot control. The mechanism is understood. Antipsychotics block dopamine receptors in a brain region called the basal ganglia. Over time the brain compensates by growing more of those receptors. When the drug dose is reduced, or when the extra receptors eventually outnumber the block, the excess drives the involuntary movements.
The prevalence is not marginal. DSM-IV-TR sets the annual incidence at 3 to 5 percent per year in young adults and 25 to 30 percent per year in older patients.³³ These are cumulative rates. A young adult after three years of exposure has a 9 to 15 percent risk. An older patient after three years has a 75 to 90 percent risk. Prevalence in outpatient clinics runs above 40 percent. In long-term facilities, above 50 percent.³⁴ There is no established treatment. Most cases are permanent.
The condition often extends beyond motor symptoms. Gualtieri and Barnhill observed that “in virtually every clinical survey that has addressed the question, it is found that TD patients, compared to non-TD patients, have more in the way of dementia.”³⁵ Breggin has called this tardive dementia. Tardive akathisia and tardive psychosis have also been documented, representing further permanent damage to the higher brain function of patients whose brains were supposed to be helped.
The condition is frequently masked by the drug that caused it. Increasing the dose suppresses the visible movements while the underlying damage progresses. Reducing the dose brings the movements out, which the prescriber may interpret as evidence that the patient still needs the medication. The patient’s brain, already damaged, is offered more of what damaged it.
The neurological literature has documented tardive dyskinesia for over five decades. It is required disclosure on antipsychotic labels. It is not routinely disclosed at the point of prescription.
Electroconvulsive therapy applies electrical current to the head sufficient to produce a grand mal seizure. In modern practice, the patient is anesthetized and given a muscle relaxant to prevent the visible convulsion. The electrical dose is often increased to compensate for the seizure threshold raised by the anesthesia. Multiple treatments are given, typically 8 to 16 per course, sometimes more.
Autopsy studies dating to the 1940s documented brain necrosis in patients who died following ECT.³⁶ Animal studies documented brain damage. The brain’s response to ECT is an acute organic brain syndrome, medically indistinguishable from severe head injury. In neurological terms, multiple continuous seizures without full recovery of consciousness constitute status epilepticus, a medical emergency defined by its risk of permanent brain damage.
The memory loss is documented in every serious study that has looked for it. Larry Squire and Pamela Slater reported an average of 27 months of retrograde amnesia surrounding treatment.³⁷ Freeman and Kendell, using face-to-face interviews conducted by the treating doctors themselves (a design that biased strongly against reporting), found that 74 percent of patients reported memory impairment and 30 percent said their memory function was permanently affected.³⁸ Squire and Slater’s own longer follow-up found that 55 percent of patients felt they had not regained normal memory function over the years.
Gøtzsche summarizes the current literature: with strict definitions of memory loss, 29 to 55 percent of patients are affected. With looser criteria, 51 to 79 percent.³⁹ Death rates from ECT, according to a systematic review by John Read and colleagues, run at approximately 1 per 1,000 treatment courses, ten times higher than the American Psychiatric Association’s stated figure.⁴⁰
The efficacy evidence is thinner than the harms evidence. The 1985 NIMH Consensus Conference on ECT accepted the finding that no controlled study showed benefit beyond four weeks. The four-week window corresponds to the acute organic brain syndrome, during which severe brain dysfunction produces the euphoria or apathy interpreted as improvement.⁴¹ Once the brain begins to recover, the depression returns. If the patient is given more ECT, the brain damage accumulates. If the patient is not given more ECT, the profession points to the returning depression as evidence the disease was chronic.
The APA’s 1990 task force report on ECT omitted essentially the entire literature documenting memory loss and brain damage.⁴² The literature it omitted included the work of Squire, Slater, Janis, Friedberg, Breggin, and even the APA’s own previous 1978 report, which contained more information on memory loss than the 1990 update. In psychiatry, science sometimes runs backward.
At some point the patient decides they no longer want to be on the drug. The system was not built to help them leave.
10. SSRI discontinuation can last years
The FDA-approved labels describe “discontinuation syndrome.” Patients and doctors alike were told the symptoms would last a few weeks and resolve. The systematic review by Davies and Read, published in 2019, established that this was false. Withdrawal symptoms are more common than reported, more severe than reported, and last far longer than reported. In one survey of 580 patients, 16 percent reported withdrawal symptoms lasting over three years.⁴³
If you are currently taking an SSRI or SNRI, do not stop it abruptly. Withdrawal reactions can include severe agitation, akathisia, suicidal ideation, and violence. Item 12 addresses the resources for safe tapering.
The Dutch tapering-strip program run by Peter Groot and Jim van Os has documented the shape of the problem. Of 895 patients on antidepressants, 62 percent had previously tried to withdraw without success. Using hyperbolic dose-reduction strips, 71 percent were able to withdraw within a median of 56 days.⁴⁴ Venlafaxine required 90 percent of patients to start at the lowest available dose and taper over three months. Some patients required more than six months. Dutch insurers refused to reimburse extended tapering because “there is no evidence in the literature” for its necessity, a circular defense against the very treatment the literature was documenting.
The withdrawal is routinely misinterpreted as return of the underlying illness. The patient is told they were unwise to stop and needs to remain on the drug indefinitely. Breggin’s term for this pattern is medication spellbinding. The drug produces effects the patient attributes to the disease.
11. Long-term outcomes are worse with the drugs than without them
The 1997 British study of a large inner-city primary care facility followed 95 never-medicated depressed patients and 53 drug-treated ones. Symptom reduction at six months: 62 percent for the never-medicated, 33 percent for the drug-treated.⁴⁵ A World Health Organization study of 640 depressed patients found that medicated patients had worse general health and were more likely to still be mentally ill at one year.⁴⁶ A Canadian five-year study of 9,508 depressed patients: 19 weeks of depression per year for the medicated, 11 for the unmedicated.⁴⁷ An NIMH study of 547 patients: medicated patients were three times more likely to lose their principal social role and nearly seven times more likely to become incapacitated at six years.⁴⁸
Rif El-Mallakh reported that 40 percent of patients on antidepressants end up in a chronically depressed “treatment resistant” state.⁴⁹ Giovanni Fava documented that drug changes induced by antidepressants “may propel the illness to a more malignant and treatment unresponsive course.”⁵⁰
The pattern extends to antipsychotics. Martin Harrow’s 15-year follow-up of first-episode psychosis patients found that those not on antipsychotics had significantly better outcomes and were far more likely to be in recovery.⁵¹ Lex Wunderink’s 7-year Dutch trial randomized first-episode psychosis patients to maintenance antipsychotics or dose reduction and discontinuation. The reduction group had double the recovery rate.⁵² Bockoven had documented in 1975 that rehospitalization rates rose after the introduction of antipsychotics and that medicated patients were more socially dependent than those treated in the pre-drug era.⁵³
The pattern is consistent across drug classes and across decades. Longer exposure produces worse outcomes. The drugs sensitize the brain and convert episodic distress into chronic dysfunction. The profession’s response has been to rewrite the natural history of the conditions to match the drug-damaged outcomes. The 1999 American Psychiatric Publishing Textbook of Psychiatry declared that older studies showing depression was self-limiting had been “disproved.” Depression became “a highly recurrent and pernicious disorder.”⁵⁴ The drugs had made it so.
12. Tapering protocols do not exist in most medical schools
The prescriber who put the patient on the drug is typically not trained in how to help them come off it. Withdrawal is not covered in the standard psychiatric curriculum. The tapering approach with the strongest evidence base is hyperbolic dose reduction, developed by Mark Horowitz and Joanna Moncrieff and published in Lancet Psychiatry in 2019.⁵⁵ The approach requires micro-dose reductions of a few percent at a time, made possible by liquid formulations or compounded tapering strips. Standard tablets do not come in the small doses required.
Peter Gøtzsche’s team spent two years trying to publish a Cochrane review protocol on antidepressant withdrawal support. The Cochrane depression group, chaired by Rachel Churchill, raised objections through 12,044 words of feedback across 86 numbered points, then rejected the protocol.⁵⁶ Cochrane refused to publish a review on how to help patients safely withdraw from a class of drugs prescribed to hundreds of millions of people worldwide. Gøtzsche’s PhD student Anders Sørensen mentored 30 consecutive patients through withdrawal in his unpaid spare time and documented the results, because it was the only way to do the work.
The insurance system compounds the problem. Dutch national health insurance refuses to reimburse extended tapering on the grounds of insufficient evidence, though the evidence exists and the insurers know it does. American insurers do not cover compounded formulations. The tapering strips developed at the Amsterdam pharmacy (taperingstrip.org) are available to prescribers in any country, but the patient must find a prescriber willing to order them, which many will not.
The knowledge exists. The Ashton Manual for benzodiazepine withdrawal has been public since 2002.⁵⁷ The Horowitz-Moncrieff hyperbolic tapering literature is in peer-reviewed journals. Mad in America hosts a withdrawal community with thousands of patients’ documented experiences. Breggin’s Psychiatric Drug Withdrawal was published in 2013.
None of it is on the psychiatric residency reading list. The doctor who wrote the prescription is, in most cases, not the doctor who can help the patient stop taking it. The patient is on their own.
The most common defense of the current prescribing paradigm is that the drugs help some patients, and that essays like this one endanger those patients by encouraging them to stop.
Some patients do report subjective benefit on these drugs. That is not disputed. What is not established is that this benefit exceeds placebo by a clinically meaningful margin, or that it survives the long-term outcomes documented in Item 11.
The safety caveats throughout this essay, and the resources listed below, exist precisely because abrupt cessation is dangerous. Nothing here recommends abrupt cessation. What is recommended is informed choice, which requires the twelve findings to be visible before the prescription is written or renewed. A patient who wishes to continue after seeing the twelve findings has made a different decision from a patient who was never shown them.
Resources
For patients currently on psychiatric drugs who wish to withdraw, resources exist outside the mainstream medical system. The Ashton Manual (benzo.org.uk/manual/) remains the standard reference for benzodiazepine tapering. The Horowitz-Moncrieff papers on hyperbolic tapering in Lancet Psychiatry (2019) provide the scientific basis for SSRI withdrawal. Mad in America (madinamerica.com) hosts an active community of patients who have withdrawn or are withdrawing. The Amsterdam tapering strip program (taperingstrip.org) makes hyperbolic dose reduction physically possible for antidepressants that do not come in the required small doses. Breggin’s Psychiatric Drug Withdrawal (2013) provides detailed clinical protocols. None of the above require permission from the prescribing physician. All require time and typically a support person. None should be attempted abruptly.
Closing
The twelve findings above are documented. They are not concealed by conspiracy. They sit in FDA labels, peer-reviewed journals, systematic reviews, and the admissions of senior figures within the profession. What conceals them is training.
Psychiatric residency does not require reading Whitaker or Breggin or Gøtzsche. It does not require examining the primary trial data on the drugs the resident will spend a career prescribing. It requires reading the textbooks the profession publishes about itself, the same textbooks that praised electroconvulsive therapy while omitting the memory-loss literature and that continue to cite the STAR*D 67 percent figure. The continuing medical education the practicing psychiatrist attends is funded largely by the pharmaceutical industry, whose interest in the twelve findings is that they should not surface. The drug representatives who visit the office once a month are the primary source of pharmacological information for many prescribers.
The doctor across from the patient in the fifteen-minute consultation is often not withholding information out of malice. The doctor does not have it. What was left out of the training reproduces itself in every consultation the doctor conducts for the rest of the career.
The training explains the local silence. It does not explain how the whole enterprise reached the point where twelve findings of this severity could accumulate without institutional response. That answer comes from someone who ran the enterprise.
Thomas Insel directed the National Institute of Mental Health from 2002 to 2015. He controlled the American federal research budget for psychiatry for thirteen years. He was, in that period, the single most powerful figure in American psychiatric science.
Reflecting on his tenure after leaving the position, he made the following observation, widely reported and repeated in the years since:
I spent 13 years at NIMH really pushing on the neuroscience and genetics of mental disorders. And when I look back on that I realize that while I think I succeeded at getting lots of really cool papers published by cool scientists at fairly large costs, I think $20 billion, I don’t think we moved the needle in reducing suicide, reducing hospitalizations, improving recovery for the tens of millions of people who have mental illness.⁵⁸
Twenty billion dollars over thirteen years, and the head of the enterprise said it moved nothing on suicide, hospitalization, or recovery.
That is not the assessment of a critic. That is the man who ran the enterprise, describing the enterprise, from inside it. Insel went on to write a book defending psychiatric drugs, so the admission cannot be attributed to conversion or apostasy. He continues to believe in the paradigm. He just concedes it produced nothing.
The twelve items above sit inside that enterprise. What the psychiatrist was trained not to tell the patient is what the man who ran it for thirteen years, on his own accounting, could not deny.
How to Explain It to a Six-Year-Old
Imagine a garage that has been fixing cars for many years. Every car that leaves the garage has a bumper sticker that says FIXED.
One day someone counts. Out of every hundred cars leaving the garage, only three actually work. Ninety-seven do not.
The garage keeps operating. The mechanics keep putting on the FIXED stickers. The owner keeps telling everyone the garage fixes seven cars out of every ten.
When someone points out that the real number is three out of a hundred, the owner says yes, he knows the real number is three. He does not correct the seven-out-of-ten claim. He does not put up a new sign. He keeps the stickers.
The people bringing in their cars do not know about the three. They see the FIXED sticker and they drive off. Some of the cars catch fire on the highway. Some of the brakes fail. Some of the cars will not start again once they are turned off.
When people bring the broken cars back, the garage says the problem is not with the fix. The problem is with the car.
That is the garage. The cars are patients. The stickers are prescriptions. The garage is a whole profession.
In Print
The Unbekoming library is available in paperback, printed to order through Lulu and shipped worldwide. The shelf begins with the paradigm question underneath everything else — No Virus, the isolation problem, the collapse of virology’s foundational claims, and a disease-by-disease reappraisal — and moves through the suppressed compounds mainstream medicine set aside: The DMSO Book, Chlorine Dioxide: The Forbidden Remedy, The Iodine Book, and The Hydrogen Peroxide Book. Two more recover what’s still on the kitchen shelf: Baking Soda and The Castor Oil Book. Two more recover the minerals modern soil, water, and processing quietly stripped from the diet: The Magnesium Handbook and The Boron Book. Sitting alongside these is No Contagion, co-authored with Jamie Andrews — the case against germ theory itself, catalogued through 258 failed contagion experiments.
The critique books cover what medicine, dentistry, psychiatry, and veterinary practice have become. The Unvaccinated treats the completely unvaccinated as a comparison group across twenty chapters and five appendices. Medicalized Motherhood follows a woman through 123 documented interventions from teenage pill to postpartum discharge. Drilling for Profit treats cavities, gum disease, and crooked teeth as the dietary problem they are. What Your Vet Can’t Tell You applies the same critique to pets. Escape from Psychiatry documents the fabrication of the DSM and the specific damage of every major psychiatric drug class. The Vitamin K Injection covers what happens in the first hours of a newborn’s life.
The full shelf is at lulu.com/spotlight/unbekoming. A physical book reaches the person a Substack post never will — the skeptical relative, the friend who won’t click a link but might open a book, the visitor whose eye lands on a coffee table. Buy one to keep, and one to give away.
New Biology Clinic
For those of you looking for practitioners who actually understand terrain medicine and the principles we explore here, I want to share something valuable. Dr. Tom Cowan—whose books and podcasts have shaped much of my own thinking about health—has created the New Biology Clinic, a virtual practice staffed by wellness specialists who operate from the same foundational understanding. This isn’t about symptom suppression or the conventional model. It’s about personalized guidance rooted in how living systems actually work. The clinic offers individual and family memberships that include not just private consults, but group sessions covering movement, nutrition, breathwork, biofield tuning, and more. Everything is virtual, making it accessible wherever you are. If you’ve been searching for practitioners who won’t look at you blankly when you mention structured water or the importance of the extracellular matrix, this is worth exploring. Use discount code “Unbekoming” to get $100 off the member activation fee. You can learn more and sign up at newbiologyclinic.com
References
Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol. BMJ Open 2023;13:e063095.
Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 2006;163:28-40.
Whitaker R. The STAR*D scandal: a new paper sums it all up. Mad in America 2010; August 27.
Whitaker R. The New York Times is now engulfed in the STAR*D scandal. Mad in America 2024; April 27.
Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Molecular Psychiatry 2022;28:3243-3256.
Hyman S, quoted in Greenberg G. The Book of Woe: The Making of the DSM and the Unmaking of Psychiatry. New York: Blue Rider Press; 2013.
Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. American Journal of Psychiatry 1970;126:983-987.
Regier D, quoted in Time for a change? Psychiatric News 2009; August 21.
Kendler KS. An historical framework for psychiatric nosology. Psychological Medicine 2009;39:1935-1941.
Insel T, address to the American Psychiatric Association annual meeting, 2005, quoted in Greenberg G. Manufacturing Depression: The Secret History of a Modern Disease. Simon & Schuster; 2010.
Pigott HE, et al. BMJ Open 2023;13:e063095. See reference 1.
Whitaker R. After MIA calls for retraction of STAR*D article, study authors double down on the fraud. Mad in America 2023; December 6.
Gøtzsche PC. Is Psychiatry a Crime Against Humanity? Institute for Scientific Freedom; 2024.
Gøtzsche PC. Mental Health Survival Kit and Withdrawal from Psychiatric Drugs. LH Press; 2022.
Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupations during fluoxetine treatment. American Journal of Psychiatry 1990;147:207-210.
Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. Journal of Clinical Psychiatry 1991;52:491-493.
Van Putten T. The many faces of akathisia. Comprehensive Psychiatry 1975;16:43-47.
Breggin PR. Talking Back to Prozac (updated edition). Springer; 2014.
Gøtzsche PC. Mental Health Survival Kit and Withdrawal from Psychiatric Drugs. LH Press; 2022.
Breggin PR. Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients, and Their Families. Springer; 2013.
Ashton H. Benzodiazepines: How They Work and How to Withdraw. Newcastle upon Tyne: University of Newcastle; 2002. Available at benzo.org.uk/manual/
Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004;18:37-48.
Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 1978;199:560-563.
Breggin PR. Toxic Psychiatry. St. Martin’s Press; 1991.
Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. Journal of the American Academy of Child and Adolescent Psychiatry 2007;46:1015-1027.
Ho BC, Andreasen NC, Nopoulos P, et al. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Archives of General Psychiatry 2003;60:585-594.
Ho BC, Andreasen NC, Ziebell S, et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Archives of General Psychiatry 2011;68:128-137.
Dreifus C. Using imaging to look at changes in the brain. New York Times 2008; September 16.
Fusar-Poli P, Smieskova R, Kempton MJ, et al. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neuroscience and Biobehavioral Reviews 2013;37:1680-1691.
Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine 2009;39:1763-1777.
Konopaske GT, Dorph-Petersen KA, Sweet RA, et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biological Psychiatry 2008;63:759-765.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington DC: APA; 2000, p. 803.
Breggin PR. Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock, and the Psychopharmaceutical Complex, 2nd edition. Springer; 2008.
Gualtieri CT, Barnhill LJ. Tardive dyskinesia in special populations. In: Wolf ME, Mosnaim AD, eds. Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. American Psychiatric Press; 1988.
Summarized in Gøtzsche PC. Is Psychiatry a Crime Against Humanity? Institute for Scientific Freedom; 2024. Historical citations include Alpers BJ (1946) and subsequent European autopsy series.
Squire LR, Slater PC. Electroconvulsive therapy and complaints of memory dysfunction: a prospective three-year follow-up study. British Journal of Psychiatry 1983;142:1-8.
Freeman CP, Kendell RE. ECT: patients’ experiences and attitudes. Annals of the New York Academy of Sciences 1986;462:341-352.
Gøtzsche PC. Is Psychiatry a Crime Against Humanity? Institute for Scientific Freedom; 2024.
Read J, Cunliffe S, Jauhar S, McLoughlin DM. Should we stop using electroconvulsive therapy? BMJ 2019;364:k5233.
NIMH Consensus Development Conference. Electroconvulsive therapy. JAMA 1985;254:2103-2108.
American Psychiatric Association. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. APA; 1990.
Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addictive Behaviors 2019;97:111-121.
Groot PC, van Os J. How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication. Therapeutic Advances in Psychopharmacology 2020;10:2045125320932452.
Ronalds C, Creed F, Stone K, Webb S, Tomenson B. Outcome of anxiety and depressive disorders in primary care. British Journal of Psychiatry 1997;171:427-433.
Goldberg D, Privett M, Ustun B, Simon G, Linden M. The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. British Journal of General Practice 1998;48:1840-1844.
Patten SB. The impact of antidepressant treatment on population health: synthesis of data from two national data sources in Canada. Population Health Metrics 2004;2:9.
Coryell W, Endicott J, Winokur G, et al. Characteristics and significance of untreated major depressive disorder. American Journal of Psychiatry 1995;152:1124-1129.
El-Mallakh RS, Gao Y, Roberts RJ. Tardive dysphoria: the role of long-term antidepressant use in inducing chronic depression. Medical Hypotheses 2011;76:769-773.
Fava GA. Do antidepressant and antianxiety drugs increase chronicity in affective disorders? Psychotherapy and Psychosomatics 1994;61:125-131.
Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. Journal of Nervous and Mental Disease 2007;195:406-414.
Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy. JAMA Psychiatry 2013;70:913-920.
Bockoven JS, Solomon HC. Comparison of two five-year follow-up studies: 1947 to 1952 and 1967 to 1972. American Journal of Psychiatry 1975;132:796-801.
Hales RE, Yudofsky SC, eds. American Psychiatric Publishing Textbook of Psychiatry. American Psychiatric Publishing; 1999.
Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019;6:538-546.
Gøtzsche PC. Is Psychiatry a Crime Against Humanity? Institute for Scientific Freedom; 2024, chapter on Cochrane.
Ashton H. Benzodiazepines: How They Work and How to Withdraw. Newcastle upon Tyne: University of Newcastle; 2002.
Insel T, quoted in Rogers A. Star neuroscientist Tom Insel leaves the Google-spawned Verily for … a startup? Wired 2017; May 11. See also Whitaker R’s coverage in Mad in America, and Levine B. How to explain top psychiatrists’ “Dr. Strangelove exuberance” unchecked by reality. Mad in America 2025; June 6.
The spokesman of Greek Fire Service confirmed at 3 p.m. on Saturday, that all six bodies of missing persons have been retrieved from the rubble of the building that collapsed early Friday morning following a powerful explosion in Plaka, the historical and touristic center of Athens. The process of identification is due. At the time […]
Search works for the missing people in the rubble of the building that collapsed after an explosion in historical center of Athens, Plaka continue until late Friday night. According to latest information, the number of the missing people has risen to six from five as initially thought. The number was officially announced by the Mayor […]
More and more creepy details and medically unacceptable practices about the death of popular singer Giorgos Mazonakis emerge as more people have testified to authorities investigating the mysterious case that sent already two doctors in pre-trial custody. On Thursday, the fourth employee at the private practice in Kolonaki, high-end district of Athens, appeared before the […]
Six hours after the explosion in a residential building in historic center of Athens, Plaka, on Friday morning, rescuers and authorities have not been able to locate three to five people under the debris of the building that collapsed. According to state broadcaster ERT, missing are: an elderly couple, permanent residents on the 2nd floor […]
A powerful explosion in an old building in historical center of Athens, Plaka, occurred at 7:30 on Friday morning. Three people injured. Building collapsed. It is unknown whether the elderly couple living there managed to survive the disaster. Injured have been two women: a 50-year-old who was trapped under the debris and another one who […]
In July 1952, reports of a railway disaster in Poland began circulating in the Western media. According to these reports, a Soviet military train derailed near the Polish town of Rzepin on 9 July 1952, killing around 160 Red Army soldiers who were returning to the Soviet Union. The train reportedly left the tracks between Rzepin and Boczów and plunged into a lake. What makes this alleged accident interesting is the uncertainty surrounding whether it actually happened.
The accident as reported by various western newspapers. Credit. Newspaper.com
From Denmark to Litochoro in western Macedonia, northern Greece, by bike: 52 days, 10 countries and 3,500 kilometers for the crazy dream of Marilena Karantini. The great journey of 34-year-old Marilena Karantinini who managed fearless this special challenge. Her thought was simple… “This year I will go from Denmark to Litochoro by bike” she said […]
Tragedy in Rhodes: A firefighter who participated in an operation to rescue tourists, died on Tuesday, after he fell from a relative high height. The 52-year-old man fell from a height and was fatally injured during an operation to provide assistance to two tourists, hikers, in an area near Sianna on the island of Rhodes. […]
Α 50-year-old high school principal suffered a cardiac arrest outside the school in Ilioupoli suburb of eastern Athens during the heavy rain- and thunderstorm hitting the area on Tuesday. Initial reports suggest the cardiac arrest was caused by lightning. Passersby who saw the woman collapsing on the street outside the school immediately called for help […]
Dès le 1er octobre, des milliers de garages pourraient perdre leur habilitation à établir les cartes grises. Pour s'y conformer, ils devront justifier de trois ans d’ancienneté et traiter au moins 200 dossiers par an. Une réforme qui entend répondre aux fraudes du Système d’immatriculation des véhicules (SIV), mais qui risque surtout de faire payer aux petits professionnels les défaillances du système public.
LE COURRIER DES STRATÈGES
Restez libre !
LA NEWSLETTER · GRATUITE
Le Courrier, chaque matin.
L'essentiel de l'actualité, passé au crible par les cinq plumes du Courrier. Dans votre boîte, chaque jour ouvré.
Gratuit. Vous restez libre de partir quand vous voulez.
Depuis 2009, les préfectures ont progressivement abandonné l’accueil physique pour les démarches d’immatriculation. Le SIV repose désormais largement sur un réseau de professionnels habilités : environ 33 000 entreprises réalisent près de 85 % des immatriculations.
LE COURRIER DES STRATÈGES
Restez libre !
ABONNEMENT
Allez au fond des choses.
Deux grands formats par jour. Les cinq plumes du Courrier. La série Sécession, le dimanche.
Trois ans d’ancienneté et 200 dossiers : le couperet du 1er octobre
L’arrêté du 21 juillet 2026 durcit les conditions d’habilitation. À compter du 1er octobre, les professionnels devront notamment justifier de trois années d’activité et avoir traité au moins 200 dossiers par an. Des garages pourtant habilités depuis la création du SIV en 2009 pourraient ainsi perdre leur autorisation s’ils n’atteignent pas ce volume.
La Fédération nationale de l’automobile (FNA), qui représente plus de 170 000 entreprises, a alerté le 11 septembre sur les conséquences de cette échéance rapprochée. Dans certaines zones rurales, le retrait d’un professionnel peut signifier plusieurs dizaines de kilomètres supplémentaires pour effectuer une démarche autrefois accessible localement.
LE COURRIER DES STRATÈGES
Restez libre !
TELEGRAM · L'INFO EN CONTINU
Entre deux éditions, le fil.
La newsletter vous donne le matin. Le fil vous donne l'instant.
La fraude du SIV sert-elle de justification à une concentration ?
La réforme intervient après la découverte d’un dispositif de fraude d’ampleur : près d’un million de véhicules auraient été immatriculés entre 2022 et 2024 par l’intermédiaire de structures fictives, avec environ 550 millions d’euros de pertes fiscales. L’État cherche donc à renforcer le contrôle d’un réseau devenu indispensable après la fermeture des guichets préfectoraux.
Mais la réponse soulève une question de responsabilité. Pourquoi un garagiste rural, qui n’a commis aucune fraude, devrait-il perdre son habilitation parce que l’administration n’a pas suffisamment surveillé son propre fichier ? Le seuil de 200 dossiers favorise mécaniquement les professionnels disposant d’un volume d’activité important, tandis que les petits garages assurant un service de proximité sont davantage exposés.
La FNA demande le retrait de l’arrêté, ou à défaut une période transitoire d’un an et un seuil abaissé à 100 dossiers. Elle envisage également un recours en urgence devant le Conseil d’État. Cet arrêté illustre une fois de plus comment la bureaucratie, après avoir failli, se retourne contre ceux qui rendent encore le service qu’elle a abandonné.
LE COURRIER DES STRATÈGES
Restez libre !
TIPS · SANS ABONNEMENT
Offrez-nous un café.
Un média libre vit de ses lecteurs. Un pourboire ponctuel, sans compte ni engagement, quand le cœur vous en dit.
Vous donnez ce que vous voulez. Vous restez libre.
An 8-year-old child was caught driving an All-Terrain Vehicle (ATV) widely known in Greece as “γουρούνα” (quad bike) at the port of the island of Paros on Saturday. The child was accompanied by a 33-year-old US national sitting on the back seat. According to some media, he was the child’s father. The vehicle had overturned, […]
A 82-year-old man was reportedly beaten to death by a 76-year-old man during a argument over a sunbed in a popular organized beach in Vouliagmeni in Athens Riviera on Sunday. According to initial information, the 76-year-old who was accompanied with a 21-year-old woman argued with the victim over the sunbed. Quickly the situation went out […]
Margaret Chant-Papandreou, second wife of former Prime Minister Andreas Papandreou, and women’s rights activist, has died at the age of 103, media reported on Friday. The American-born women’s rights advocate played a prominent role in efforts to strengthen the legal and social rights of women in Greece. Chant-Papandreou was the wife of former prime minister […]
The two doctors suspected for the death of popular singer Giorgos Mazonakis have been remanded in custody following a 17-hour testimony before an investigating magistrate that concluded early on Wednesday. Both the investigator and the prosecutor ruled that the couple of doctors must be held in pre-trial detention on charges of homicide with potential intent. […]
As both the Navy and the USAF were racing to field a new generation of advanced tactical jets, the seagoing service’s program hit a wall. A major reason behind this from the Pentagon was concern that the U.S. industrial base could not handle simultaneous final development and production of two extremely complex new fighter aircraft. This was a controversial justification that many had a hard time swallowing. The Navy’s program, dubbed F/A-XX, is supposedly back on and a down-select on who will build it is coming soon, but that concern appears to linger among at least one of the Department of War’s top acquisition officials.
Though he remains confident that the U.S. Air Force F-47 sixth-generation fighter will fly in the next two years, Air Force Gen. Dale R. White, Director, Critical Major Weapon Systems — the service’s leading weapons procurement advisor — remains concerned about the overall capacity of industry to provide the military with the aircraft it needs, including two new fighters. His comments were in response to questions about the Navy’s challenges in building its own sixth-gen fighter alongside F-47.
The concerns are “not unique” to the F-47 or the Navy’s program but the problem exists to various degrees across the industrial base too, White told reporters Tuesday during a media roundtable at the Air & Space Forces’ Air, Space and Cyber Conference that TWZ is attending.
White has a dual-hatted role, serving as the Pentagon’s top weapons procurement officer and as the senior acquisition advisor to the Secretary of the Air Force for all acquisition matters.
A rendering of the F-47. (U.S. Air Force) U.S. Air Force
“We’re seeing it in multiple platforms,” said White, who did not elaborate. “And so what we’re having to do is, at some point, we’re having to make some trade space in between some of these.”
“I see Boeing making smart investments,” White said of the prime contractor of the F-47, selected for the U.S. Air Force’s Next Generation Air Dominance (NGAD) ‘fighter’ initiative. “They have a lot of CAPEX [capital expenditure] that they’re pouring in, but we have to get through the process of the design piece, getting that completed and closed out. Then we all hit some major milestones with things like flight tests and software and those things.”
F-47 specifications infographic (USAF)
“Really, it’s just being able to manage the overall resourcing as it relates to number one, people resources,” the general added. “Number two, when you start getting into the production conversation, do we have enough capacity to be able to produce at that rate? And so, by and large, I have concerns. I have concerns about the capacity of our industrial base, but they are not unique to F-47 or to any program.”
As for the F-47, White said the program “continues to progress exceptionally well.”
“As you know, many, many years in tech maturation and risk reduction gave us a tremendous head start on this program,” White explained. “Extremely proud of what the team has done, what they continue to do each and every day. We are still absolutely on [the] path to be able to hit the mark of flying within this administration. So we see no issues in front of us right now.”
While the first example of the F-47 has been in production for about a year now, the Navy has yet to even select a prime contractor for its next generation fighter. The current competitors for the F/A-XX are Boeing and Northrop Grumman. A decision was supposed to have been made by last month.
“The F/A-XX program remains on track, and we have no further information to provide at this time,” a Navy official told us last week.
In response to a question from TWZ earlier this year, the Chief of Naval Operations acknowledged the uncertainty over the F/A-XX program.
“One of the challenges we’re seeing is, not only [are] our peer competitors improving their capability for anti-air, either air-to-air or surface-to-air, but the lower cost of entry of very capable weapons is also making more players on the field in which that level of stealth and technology is required,” Adm. Daryl Caudle told us back in April at the Sea-Air-Space 2026 exposition. “So this is not about the need for a peer adversary. This is just having an aircraft that can operate with a level of uncertainty and with the acceptable level of risk.”
With Boeing as a finalist, it is also possible that F/A-XX could be a variant of the F-47. As we noted in a past story, the Boeing render for its F/A-XX concept is remarkably similar to artwork for its F-47.
Last year, Steve Parker, Boeing Defense and Space CEO, said he didn’t see a problem with his company building both jets stating that this had been part of the strategy all along.
If this is the case, the company’s claim that it would not have a problem building both the Navy and Air Force next-generation fighters would make more sense. There are a number of advantages when it comes to establishing a high-degree of commonality between F/A-XX and F-47, although there would also be challenges, especially when it comes to getting the most out of a design that was not meant to operate from a carrier deck and scaling production up for both services. There is already significant sharing of elements of both the Navy’s and Air Force’s sixth-generation fighter programs. So commonality in some subsystems and interoperability are already baked in.
We should hopefully finally get a clearer picture in the coming weeks about the status of the F/A-XX and possibly the answer to who will actually build it, which will give us a better idea of what the industrial base impact actually will be.
European Commission President Ursula von der Leyen paid tribute on Wednesday to the Danish and Greek pilots who lost their lives while fighting wildfires in Greece, saying they had died as heroes. The two pilots were killed during a collision of two firefighting helicopters trying to extinguish a big forest fire in western Attica on […]
After running a historic campaign to unseat a criminal court judge for the first time in Nashville, Courtney Teasley created the legal education company emeffen to inform working-class communities about their civil rights. From combating police abuse to supporting vulnerable populations targeted by the criminal justice system, Teasley is a business and legal powerhouse redirecting people toward civic engagement and political-economic acumen. In this heartfelt interview, Mansa Musa and Courtney Teasley discuss grounded community organizing and political education that subverts the carceral system’s goal of turning citizens into captives.
The following is a rushed transcript and may contain errors. It will be updated.
Mansa Musa:
Welcome to this edition of Rattling the Bars. I’m your host, Mansa Musa. Today we are joined by Courtney Teasley, who consider herself and identify herself as a legal disruptor and justice strategist. We’ll be discussing her perspective on how she is intervening in the criminal injustice system and her work challenging the prison industrial complex as it exists today. Thank you, Courtney. Welcome to Rattling the Bars.
Courtney Teasley :
Thank you so much for having me. I’m really excited. I’ve heard a lot about this podcast, and so thank you so much for this opportunity to talk to your audience.
Mansa Musa:
Okay. Let’s start by introduce yourself to our audience and tell our audience how you came into this space, but more importantly, what is a legal disruptor and a justice strategist? What’s your identity as how you identify those things? So tell us a little bit about yourself.
Courtney Teasley :
Yes. So my name is Courtney Teasley. I am a licensed attorney in Nashville, Tennessee. I have practiced mainly criminal defense for the last 13 years and am now a retiring lawyer, a criminal defense lawyer, because I have done all the things within the criminal justice system from teaching and training in mock trial, training and coaching other lawyers to open their own law practices, and also then to teaching as a criminal justice educator over at a historically black college and university here in Nashville called Tennessee State University. So I taught there for a number of years as well. And then that is where I was able to see the big three that were creating this cycle. I call them the big three education topics that people from what I like to call the DAMM community, D-A-M-M, and that’s the disproportionately affected marginalized minority community. And people from that community are often not educated in the big three that I call financial literacy, criminal justice literacy, or legal literacy, and civics.
And these three lead directly to mass incarceration. And so after running a campaign, it was a historical campaign here, we unseated a criminal court judge for the first time ever in Nashville. I decided to create a legal education company to help fill that gap of legal literacy that so many of us never received and that basically you had the cops saying, “Hey, ignorance of the law is no excuse for breaking the law, but you never taught me the law.
That’s legal literacy and then financial literacy. You keep me in cycles of poverty. You keep me broke. You don’t teach me ever how to really make money.” And so that leads right back into the criminal justice system. And then finally civics, the last one we’re undereducated in, you teach us nothing more than go vote. You don’t teach us anything else around how to actively participate as a citizen. So we don’t really take advantage of the things that we should. We don’t really hold people accountable the way we should. We don’t show up the way we should when it comes to voting because of that. So that’s why I created my company is called MFN and I created it with the intent to help reduce mass incarceration.
Mansa Musa:
Okay. And it’s interesting that you identify three areas that you say are essential in disrupting this cycle. So let’s talk about those. Let’s talk about those things. Walk us through your program. How do you engage the community or who is your target audience?
Courtney Teasley :
Yeah, so like I was kind of telling you why I created it, I forgot to mention a very important part of that all the things we do are proactive in the criminal justice system, meaning I feel like if mass incarceration is going to go anywhere, the efforts to fight it must happen before someone has been found guilty or someone has pled guilty. We know 97% of people take pleas. And so the majority of efforts in the criminal justice system usually are happening after someone has already pled guilty and been found guilty. They have received that ultimate if, made a felon. Their rights may be restricted. They have a lot of different things. They have a lot of different hurdles at that area versus fighting proactively where I think we can be a lot more strategic and a lot more effective. So that’s my company focusing in on the proactive portion of fighting back.
And so how we do this and how I engage in the community, and I think you asked me also who is my targeted audience. And so the ways that we’ve been. My target audience is who I was telling you, the damn community, disproportionately affected marginalized minority community, the 97% of people who take pleas, the people from areas of town that others may look down on. I’m talking about the hood.
The people who most likely come into contact with the criminal justice system, that’s my target audience. And so we engage the community through multiple efforts, whether it’s through our partnerships and collaborations with schools, churches, community centers, organizations that care, from us going out and creating the activations where we’re bringing the legal literacy, but we’re bringing it in a fun way where people actually want to take part in and they’re getting to understand it, they’re getting to participate. So we do that and then we do some advocacy training where now we train organizations how to fight back proactively. So I’m a criminal defense attorney and when I say a justice strategist, I’m a fighter and I’m a strategic person first. And
So I’m going to pull back the veil and I’m going to show you what the criminal justice system really is and then I’m going to teach you how to do what I teach my lawyers how to do, play chess and not checkers, how to fight back unapologetically, vigorously. And so that’s what we do in our advocacy training. And so that’s how we engage the community. A lot of times we’re doing events where we’re going out to people who are having events in the community and a lot of people just don’t feel competent in teaching legal stuff. And so we bring that to you because we speak the language of the damn community, D-A-M-M community, African American English.That’s how I’m so successful as a lawyer because I’m bilingual. I speak two languages and that’s how the community resonates. If my life is on the line, I don’t need you speaking above my head.
So that’s how we engage in the community in an authentic way.
Mansa Musa:
When you saying legal literacy, are you educating me on understanding my rights somewhere like the Black Panther Party had, when they came out, they was going around, they was telling people they had the right one to be on, but they wasn’t saying your right to bear saying you have a right to be arm, but you have certain rights when the police pull you up and stop you. You have a right to not say nothing. You can ask to speak to somebody. When you say legal literacy, you talking about pre, post incarceration or do you deal with people at all sectors, like a person in society or people in prison or people that got out on what we call paper, out on parole?
Courtney Teasley :
Yeah. So with legal literacy, when I’m speaking about that, we’re talking about all facets of it. So I have books already for the Fourth Amendment, the Fifth Amendment, books on that. And I teach out on the Sixth Amendment because that book is not out yet. We have plenty of books that are coming out, but the Fourth and the Fifth Amendment, the Fifth Amendment is the one that just came out. And actually I’ll send y’all over a copy of it so you can check it out.
But the way that we really just break, it’s packed full of pre-protection. Now, and when I say pre-protection, that means protection that jumps in from the moment you’re accused of anything. A lot of times we like to rely on the Fifth Amendment and wait until the police tell us, oh, you got the right to remain silent or you’re being forced to testify and you’re like, oh, I plead the Fifth. However, no, the Fifth Amendment, it actually came into play the very moment you were suspected. So when that cop gave you a call and said, Hey, I want to talk to you, you know what I mean? We’ve heard from such and such. You mind coming down here talking to me? At that moment, even though they haven’t told you that you’re a suspect or whatever it may be, you have the power to say, oh, hold on.
I think I’m going to choose to stay silent. I’ll have my lawyer contact you. So you get to make a determination whether it’s in your best interest to talk about anything. So you have that pre-protection. And so that’s how we kind of engage with the amendments that really pop up in the criminal justice. The fourth, fifth, and sixth are the ones that we focus in on when we’re teaching our advocacy training. But those come into play when you’re incarcerated.
If you’re just on bail and you’re waiting, well, those are in play. Or even if you’ve been found guilty and you’re appealing, those are in play. You need to be able to understand those. And so then for other ones that we don’t have books on, then you rely on a person like myself to be able to train you on what that means for your organization or your specific
Mansa Musa:
Situation.
Courtney Teasley :
Okay.
Mansa Musa:
Yeah. And then in financial literacy, because I was telling off camera that when I got out, I hadn’t established no credit, but I had established a savings. So when I went to get an automobile, my mind was I ain’t want no car note. So I wind up paying $15,000 for 2015.
Courtney Teasley :
Oh
Mansa Musa:
God. And had I had established credit, I would’ve had made out better. But since then I had established credit. I went to a dealership in 2023 and I had the same amount of money and because I had good credit, I was able to get a 2023 and I paid the same amount of money I paid to get for that 2015. So my concern with the financial literacy, what is this? Because when you talking about the damn community, a lot of us don’t have a pot to piss in the window to throw it out. So we don’t have no funds. So are you teaching how to create your own business? Are you teaching how to go about getting grant, how to get money and then how to manage it? What is this, your financial literacy model? I
Courtney Teasley :
Love that you asked that. So after I declared retirement from the practice of law, I went and got certified as a business coach and I’m also a certified strengths coach. And so I basically am talking, when I’m teaching about financial literacy, I did that to go be able to teach my lawyers who were never taught anything about business. But when we transition it over here to people in the damn community, we started the very basics, like you said, learning about building credit. It’s just something so simple that it’s like a lot of times we don’t think about it or we’ve been so used to having not so good credit that we try to disregard it, that we never try to maybe get it back together. Well, and I understand that, but I think that there are multiple ways that you can start building your credit in smaller ways that a lot of people don’t talk about.
So we like to bring in financial strategists and people who are investors who actually have done these types of things to help you understand what to do. A lot of times, think about it like this. When you were just talking about you had a savings and the thing is you’re thinking about how can you make more money? How can you do whatever? You got your job. Then it’s like, well, who is here teaching us about investing? These are things we never learned about. Nobody’s sitting here giving us the playbook on what to do or how to do it. Like you said, you might be working a dead end job, a job that doesn’t promote you. Well, then you need to learn about what kind of jobs are out there, what kind of jobs, what kind of skill set do you have? What have you already done?
And then how can we use those same skills to get you a job that now has advancement opportunities? So it’s just all of those things that come together and that comes with us partnering with other organizations and actually bringing the experts to you to be able to help understand how do I segue now? I have not partnered yet and I’m open to it. I have not yet partnered with an organization for reentry where we’re teaching the coaching to them, but I have connections with one of the world’s top traders just in the last couple of years. I did an interview with him and he’s actually a Nashville native and he came down and he did a gig where he just talked to us all about investing, the bare minimum, how to start, what to do. Then you want to get somebody else. What’s a 401k?
How do I start it? What’s the IRA? You bring the experts to be able to bring it down, take all the high paid jargon out of it and speak the language of the damn community and explain to me, how do I get my ducks in a row? How do I protect myself and my children? And so that’s what I think we do well with partnering with other orgs to help
Mansa Musa:
That. And then we talk about civic and that in of itself speaks volumes in terms of our lack of understanding of electoral process, our lack of understanding of different institutions that regulate, responsible regulatory type things that affect us. So what is your civic model? Because when we learn civic in school, we know that at a certain age you get a right to vote. We know now that that’s not a guarantee with the latest Supreme Court decision, but be that as may, what’s your civic model?
Courtney Teasley :
Yeah. So with civics, my big thing has always been people get so mad, especially the new generation, it’s like, oh my God, they don’t vote. They won’t do this. They won’t do that. And it’s like, well, you got to teach them more than just go vote. It’s more to civics than just going to vote. And I like to bring up a case that I was fighting vigorously back in 2023. It was called disruptmanchester, if you look on Instagram or Twitter. And a family with five children, five Black children were driving through Manchester, Tennessee and had their children taken and forced into foster care all over marijuana. And so in that case, I had to publicly put it out to people and let them know what’s going on in this city that we consider a sundown town. A lot of Black people have known it to be that over the years.
And so we know what it is when these people are taking Black children and forcing them into foster care. And so when you’re making it public and you’re letting other people know what’s going on, and basically I call it criminal defense organizing, “Hey, this is what they’re doing to us in real time. We need you to be concerned about what’s going on.” I want to ignite their civic abilities and a lot of times they have to know what that means. And your civic abilities just meant, “Hey, you got the power to come court watch. You know that you can come. You have a right to come into a courtroom. You have a right to sit in here and see what they’re doing.” That’s accountability, making sure that the people that your taxes pay, that they’re accountable to you. And then also when we had issues where we were saying, “Okay, well, you guys took the children.
The state trooper did this, the county did this.” Well, people started to request records. So as citizens, like, “Hey, I’m requesting to see the stop. I’m requesting to see your personnel records. I’m requesting…” So that’s the type of thing when you’re igniting people to understand that as a citizen, because government officials, public officials, you pay them, your taxes pay them, you have the right to inquire into anything that’s going on, and you have the right to demand answers, you got the right to transparency, you got the right to ask for, you can file complaints, you can come court watch. So igniting them to see that your civic duty far exceeds just voting, right? You have power and you just need to know how to utilize it.
Mansa Musa:
In the District of Columbia, before you answer, we got the right returning citizens. Anyone formerly incarcerated, you’re a DC resident, you got the right to vote. And so we got that right. But with this latest decision that came out the Supreme Court, we looking at how they might try to take that back because the federal government got complete control over the District of Columbia, everything relative to District of Columbia, the federal government. We’re not a state. We got home rule. So talk about how you look at people that’s disenfranchised because that’s your costume population specifically. And not only that’s them and their family, because their family is highly affected by their incarceration.
Courtney Teasley :
Absolutely. So basically with what you’re talking about is probably going to go more into efforts that are reactive, but very necessary. And so what I did recently is incorporate a nonprofit so that way we are able to partner with organizations that do a lot of the rights restoration. And so most recently we hosted a judicial forum and in the judicial forum, we talked about, we educated them first on what all these seats, because right now we have a special election for judges going on right now. So we educated them around that. And then we had a forum so they could hear from the people. But one of the big pieces was we wanted people who did not have their rights, who may have been made felons at young ages. We wanted them to be able to come in and inquire about how to get your rights back so we can start that process with them.
And so what we do is we’ll have them come in, let us know, “Hey, I’m interested in getting my rights back or however, just let us know you’re interested.” And then we can do the connections with making sure you get that done. And we do that through collaborating with other orgs who are already doing it. So that’s how we try and fight back reactively by partnering and empowering, kind of like you were just saying, how you give amplify people’s voices. So we try to do that with other organizations. We’ll connect with them and allow them to do what they’re doing best in that field around rights
Mansa Musa:
Restoring. Yeah. And I mentioned earlier that I was incarcerated. Prior to being released, I did 48 years in the Maryland system. And a lot of what you’re saying, we would educate ourselves on all those levels. You had guys that did financial listing, they studied the stock market. They understood it and they invested their money. We had people that was jailhouse lawyers and did legal and was proficient at that. And then we had people that came together around organizing the community around social issues in general. If a person, and I’m looking at the prison population in particular, if a person in the prison population, when they let me out, they gave me $50.
They didn’t give me no bus ticket. They let me out in the city. They let me out in Baltimore City. I reached out to my family. I ain’t know if they had got the message or not, but that’s what I left out with $50 after serving all that time. The average person leave out a prison in the Maryland system with about that much money before they leave. If they leave with any kind of money, it’s not enough money for them to sustain themselves. So what’s your economic, that component and why you call it the missing curriculum and how do that factor into the system eradicating it or stabilizing the people that’s coming out?
Courtney Teasley :
Yeah. So I love that you asked this and I think you’re talking about when I call it why financial power is a prerequisite for social justice. Because one thing for me is as a criminal defense lawyer, I didn’t take the public defender route. I didn’t want to work for the government. I didn’t want my hands tied. I didn’t want to go to handcuffs. I wanted to be able to fight because the moment you fight a little too hard, guess what they going to do? Take your money from me, right?
Mansa Musa:
Yeah.
Courtney Teasley :
So that’s the way they keep us in order. And so I wanted to be able to fight without having that issue. And so I started to see that the fact that I was private practice, I was able to create, I charged my worth the majority of the times, but because of that, I was able to create scaling fees, sliding fees, low income, and represent people who really needed it because I charged my worth over here in my law practice the majority of the time. The people who can’t afford it were able to pay that and the people who were not able to afford it, I’m still able to represent you because I get to create that. I didn’t need the government to tell me to do a pro bono or to take a court appointment. I knew how to serve my community. And so one thing I kind of started to see is I would do all the things.
I told you I did the mock trial. I was the NAACP legal redress chair. I was the equality and justice committee chair for the Tennessee Association Criminal. I was all these things. And I started to see that real change. Y’all trying to burn me out. You know what I mean? And you’re not going to pay anybody for it. So I started to see that if the narrative being pushed is if you want to help your community, you need to do it for free and long hours, do it under a nonprofit, don’t get paid much. And I was like, well, that’s the reason none of these initiatives are long lasting.
Mansa Musa:
They
Courtney Teasley :
Only last for a little bit of time. And then as soon you run out of money and then now you can’t help anybody else. And so what we have to do is be able to be self-sustaining. So when people in our community are creating businesses, when I had my legal education company and 10% of all my product profits go back into the very people who are fighting proactively. So one of the Middle Tennessee National Action Network, I trained them and my trainings was $5,000. Well, they didn’t have to pay for that because people that actually were supporting and buying our product books and buying into our other things. And so that is, to me, a model that other businesses can take and see that, look, there are problems in our community. I’m making money over here. Well, let me figure out how to best assist.
And then that means in your situation, when you’re talking about a person coming from prison, well, if you have a business that actually cares, that you’re partnering with a business and they’re like, you know what? This is hard. People are trying to get back on their feet. We want to be able to make sure that they can do just that so that person can come and maybe they can do an externship. They can get a job over here and then they can get a stipend up front. Whatever it is, we are the ones who have to create the solutions. Nobody’s coming to save us. And the solutions that are coming through nonprofits are the monies. Come on, we’re under this administration. A lot of people aren’t getting money for anything that’s assisting Black people in general. So it’s going to be up to our community to be able to build financial power, to be able to become financially literate and to be able to be creative in actually helping assist.
For me, I care about any mass incarceration. For somebody else, it could be something different, but it’s going to be up to us to create those solutions and then partner with the ones that are doing it.
Mansa Musa:
And I think your approach to this mindfulness and skill building, it goes back to an era where we was educating for liberation. So I think we get caught up on how we see the problem and therefore we let that be determined the solution. But more importantly, who telling us what the problem is? Not so much as it how we see it. Let me rephrase that. Somebody telling us this is what the problem is, and then we say, okay, then the solution is, and trying to get a solution, it become, to your point, we try and get something from the government and the government ain’t going to fund you to get your freedom. That’s not happening. Government ain’t going to come and say, okay, because we still waiting on our 40 acres of the mule. And
Courtney Teasley :
It ain’t
Mansa Musa:
Coming. It ain’t coming. So the best thing we can do is do what we’ve been doing. But Courtney, I really appreciate you coming and having this conversation. And I hope our audience can really understand the importance of this approach, mainly when you’re dealing with the cost population. I know from experience that when people come into that system much like yourself and provide education, information and knowledge that we’re receptive. And there was a lot of people that was locked up with me, all of us that got out in the last 10 years. And a lot of what we learned while we was incarcerated, we’re doing it now in the Baltimore community and other communities. But you got the last one. What you want to tell our audience about how they can get in touch with you and how they can support your work?
Courtney Teasley :
Thank you so much, Mansa. First of all, what you just said is exactly why I’m doing the work I do and why I focus proactively prior to someone becoming incarcerated, prior to someone taking a plea or pleading guilty because I think it sucks that you did 48 years. Could you have helped me prior to that? And a lot of times you’ll see the Innocence Project, which is good and they’re doing good work, but it’s like people are only getting out and that effort’s only coming in after people have done 30 and 40 years. And it’s like, I think we can do something way before then while they’re fighting their cases more proactively. And so you can find me over on TikTok. I do a lot of legal literacy education over there. I have a whole course up there called Easy Way to On Your Right.
It’s Criminal Justice Literacy 101. It went most viral. We have over 30,000 followers and we have so many resources like a fight your case manual. So anyway, come over and follow us at MFN, that’s E-M-E-F-F-E-N. And we’re also over on, if you want to follow me personally, you can hit me up on LinkedIn, Courtney Teasley, or you can find me on Instagram @thecourtneyteasley. And so YouTube, again, we have the same thing. It’s not MFN, it’s @blacklawgirl. So if you want to find us on YouTube, it’s @blacklawgirl.
Wherever I am, look, come find me, come get me, and let me know. I love to come collaborate with y’all wherever you are. Let me bring the legal literacy and let me bring it in a fun way that’s easy to understand.
“A Black family with five children [was] driving through Manchester, Tennessee, and had their children taken and forced into foster care all over marijuana. ... I had to publicly put it out to people and let them know what's going on in this city that we consider a sundown town. ... We know what it is when these people are taking Black children.”
Login
